With the support of the Seaside’s funding, Vanderbilt researchers are expected to use medicinal chemistry, molecular biology, pharmacology and efficacy studies to develop compounds that have the properties required for drugs to be used for further study in fragile X.
Seaside Therapeutics will collaborate with Vanderbilt on this project by contributing scientific and drug development expertise, particularly as related to fragile X syndrome, autism and other disorders of brain development. Seaside will also select compounds from the collaboration to carry forward into clinical development.